lar, infections caused by the hepatitis C virus resist the body's attempts to develop immunity, leading to persistent infection and chronic liver disease in a large percentage of those infected (CDC, 1996b) .
Occupational and environmental health nurses need to be familiar with managing hepatitis in the workplace. Employees with the potential for exposure to blood and other potentiall y infectious fluids are at an increased risk of contracting hepatitis B, C, and D. Employees traveling to developing countries also are at increased risk of contracting viral hepatitis. Additionally, employees working with certain chemicals are at risk for developing acute toxic hepatitis.
This article differentiate s among the various types of viral hepatitis with respect to epidemiology, transmission, diagnosis, course of infection, treatment , and education/prevention. In addition, hepatitis due to chemical exposures and secondary to other illnesses is addressed. Finally, nursing implications are discussed .
GENERAL OVERVIEW Background
Hepatitis is an inflammation of the liver ("hepat" ::: liver; "itis" ::: inflammation). It can be caused by viruses, bacteria, drugs, alcohol, chemicals, and autoimmune diseases.
The liver performs several vital functions for the body. It detoxifies and neutralizes substances such as chemicals, drugs, and alcohol ; produces bile; regulates blood clotting ; controls the production and excretion of cholesterol; stores sugars, vitamins, and minerals; produces quick energy; and manufactures new proteins (Hepatitis Foundation International, 1997) . The liver is able to regenerate unless irreversibly damaged such as during cirrhosis. During cirrhosis, the liver is scarred, becomes smaller, and hardens.
Transmission
Viral hepatitis A-E are communicable diseases that can be transmitted to individuals through a variety of routes. These are described in detail in the following sections. Chemically induced hepatitis occurs due to exposure to a variety of different workplace substances (see section on acute toxic hepatitis).
Diagnosis
Although infected with distinctly different viruses, individuals presenting with acute viral hepatitis present with similar clinical manifestations. Common early symptoms include fatigue, anorexia, nausea, low grade fever, and pain or a dull ache in the right upper quadrant. Most of the symptoms diminish when jaundice develops or shortly thereafter. On physical examination, the most obvious features are icteric skin and sclerae. The liver may be enlarged and tender to palpation (Perrillo, 1997) .
Course of Infection
The clinical course of hepatitis can range from 206 asymptomatic to self limiting to life threatening acute and chronic disease. Chronic hepatitis can follow hepatitis B, C, and D. Most individuals with chronic hepatitis B develop cirrhosis, often within 10 years of diagnosis. Individuals with chronic hepatitis D infection usually progress to cirrhosis more quickly. Chronic hepatitis C also can lead to cirrhosis, although it may take 10 to 20 years to do so (Main, 1997) .
The morphologic changes in the liver often are identical in the various forms of viral hepatitis. Once the acute phase of disease has passed, the liver usually returns to normal.
Treatment
No specific treatment exists for typical acute viral hepatitis, and appropriate supportive measures are provided. Hospitalization may be indicated for individuals with clinically severe illness, dehydration, failure to maintain nutrition, and high risk factors such as advanced age, pregnancy, or presence of other illnesses. Although restricted physical activity is not essential, individuals may feel better with bed rest. A high calorie diet is desirable. Intravenous fluids may be necessary for dehydrated individuals. Alcohol and drugs metabolized by the liver need to be avoided (Perrillo, 1997) .
EducationlPrevention
General Preventive Practices. Infection control measures minimize the risk of exposure to viral hepatitis. Universal precautions must be used for all clients. Universal precautions include wearing appropriate personal protective equipment (e.g., gloves, masks, protective eye wear, etc.) when contact with potentially infectious fluids is anticipated. "Potentially infectious fluids" include: • Blood and blood products. Enteric precautions are used for individuals infected with pathogens transmitted through the fecal-oral route.
Vaccination. Pre-exposure and immediate postexposure vaccinations can serve as primary and secondary preventive measures for hepatitis A, B, and D.
Occupational and Environmental Health Issues
If an employee presents with flu like symptoms and hepatitis is suspected, a thorough history and physical evaluation need to be conducted. The history needs to include questions about past exposure to potentially infectious body fluids, travel to developing countries, exposure to individuals with known hepatitis, and alcohol intake. During the physical assessment, the liver span should be assessed.
The nurse needs to identify populations at risk and provide counseling and prophylaxis (e.g., vaccination) as needed. Return to work issues are addressed on a case by case basis (see specific sections below).
Anti-HAV Prevalence
• High Intermediate D Low Figure 1 . Geographic distribution of hepatitis A prevalence. From CDC (1997b).
HEPATITIS A

Background
The hepatitis A virus (HAV) is a RNA containing virus . Major risk factors for acquiring hepatitis A include personal contact (e.g., household or sexual contact) with a person who has hepatitis A, contact with young children attending day care , travel to developing countries, and food or waterborne disease outbreaks (CDC, 1996a) . Once infected with the HAV, an individual develops antibodies to the HAV (anti-HAV) .
Epidemiology
The HAV is found worldw ide . In a survey conducted in the United State s during 1988-1991 , 33% of the population was determined to have serologic evidence of prior HAV infection (CDC, unpublished data) . Anti-HAV prevalence rates were found to increase with age. Anti-HAV prevalence is highest among Mexican Americans (67%), compared with blacks (37%) and whites (29%) (CDC, 1996a) . HAV is highly endemic in developing countries including Mexico, South America, Africa, etc . (see Figure 1 ).
Transmission
The HAV is found in feces, serum, and saliva of infected people. The primary source of infection is by the fecal-oral route by either person to person contact or ingestion of contaminated food or water (CDC, 1996a) . Although not common, transmission of HAV by transfusion of blood and clotting factor concentrates obtained APRIL 1998, VOL. 46, NO.4 from donors during the incubation period have been reported (Benenson, 1995) . Transmission by saliva has not been reported to occur (Cohen , 1989) .
HAV can produce clinical disease in susceptible individuals. Foodborne outbreaks are most often due to uncooked foods or foods touched by contaminated human hands after cooking. Water, shellfish, and salads are the most frequent sources. However, cold cuts and sandwiches, fruits and fruit juices, milk and milk products, vegetables, and iced drinks also may be culprits (U.S. FDA, 1991) . Food outbreaks also have been reported in association with foods contaminated before wholesale distribution such as strawberries (CDC, 1997a; Niu, 1992) and lettuce (Rosenblum, 1990) .
Diagnosis
The first viral marker to appear is hepatitis A antigen in the stool. Thisappears during the incubation period, about a week to 10 days before the onset of illness. The antigen generally disappears within 2 to 3 weeks after the onset of illness. The next marker to appear is the serum IgM antibody against HAV. (IgM anti-HAY). IgM anti-HAY usually is detectable by the time symptoms appear and usually is detectable for 3 to 6 months after the onset of illness. Acute hepatitis A infection is diagnosed when the IgM antibodies against HAV (IgM anti-HAY) are identified in the serum. Presence of IgM anti-HAY implies ongoing or recent infection with hepatitis A. This is followed by another class of antibodies, IgG anti-HAY, which can persist indefinitely and confer immunity against reinfection (perrillo, 1997) .
Course of Infection
Infection with HAVis usually self limited, lasting 1 to 4 weeks. However, relapses may occur for up to 6 months (Alter, 1994) . Infection can cause either asymptomatic infection or symptomatic infection after an average incubation period of 28 to 30 days (range, 15 to 50). The illness produced by HAV typically is abrupt in onset and may include fever, malaise, anorexia, nausea, abdominal discomfort, dark urine, and jaundice (Benenson, 1995) . Hepatitis A is usually a subclinical disorder in children. On the other hand, adults are usually symptomatic (Lednar, 1985) . Chronic HAV infection does not occur (Perillo, 1997) .
Although the overall reported case-fatality rate for HAV infection in the United States is low (< 1 per 1,000), high case-fatality rates have been reported among children younger than 5 years of age (1.5 per 1,000) and among persons 50 years of age or older (27 per 1,000) (Benenson, 1995) .
Treatment
Treatment for hepatitis A is supportive.
Education/Prevention
General Preventive Practices. The following preventive measures have been recommended (Benenson, 1995) (CDC, 1996a) .
Vaccination. Protection against hepatitis A may be provided through either the administration of immune globulin (IG) or the hepatitis A vaccine.
Immune globulin provides short term, immediate protection through the passive transfer of antibodies to an individual. IG is a preparation of processed, concentrated antibodies (immunoglobulins) made from pooled human plasma which has tested negative for the hepatitis B surface antigen (HBsAg), antibody to human immunodeficiency virus (HIV), and antibody to hepatitis C virus (CDC, 1996a) .
Immune globulin has been found to offer immediate, effective passive protection from hepatitis A. This is beneficial for individuals who, for example, have not previously received the hepatitis A vaccine and will be traveling within the next 2 weeks to areas that have high or intermediate endemicity of infection. However, protection is short term and readministration is needed every 3 to 6 months for continuous protection. This may become expensive, logistically complicated, and difficult to main-208 tain due to unreliable supply to ensure sufficient long term protection. Of note, the availability of IG has recently been very limited. Highest priority for IG use is directed toward post-exposure prophylaxis following exposure to hepatitis A. Thus, use of the hepatitis A vaccine is generally preferred for pre-exposure prophylaxis.
Hepatitis A vaccines currently licensed in the United States are Havrix (SmithKline Beecham Biologicals) and Vaqta (Merck & Company, Inc.). Antibodies to HAV have been identified in nearly 100% of adults 4 weeks after vaccination (CDC, 1996a) . Studies have demonstrated protection in adult recipients 15 days after a primary vaccination. For example, between 80% and 98% of adults developed protection 15 days after the first dose of Havrix (CDC, 1996a) .
The hepatitis A vaccine is given intramuscularly and needs to be followed by a booster dose. Vaccine induced antibody titers have been found to persist after a primary vaccination course for 1 year or more. Although data concerning the long term persistence of antibody to HAV are limited, individuals receiving the booster dose at 6 to 12 months are expected to have long lasting protection, calculated to be more than 20 years (Clemens, 1995) . Immunosuppressed individuals may need additional boosters.
Studies to determine whether vaccines from different manufacturers may be used interchangeably in a series are planned. Until this information becomes available, it is not recommended that Havrix and Vaqta be used interchangeably in a series for an individual. However, if the manufacturer of the initial vaccine is not known for an individual due for a booster, it is recommended that the booster dose be completed with the vaccine from either manufacturer rather than restarting the series (American Academy of Pediatrics, 1996) .
The CDC (1996a) recommends hepatitis A vaccination for persons at increased risk for infection and for any person wishing to obtain immunity. Populations at increased risk for HAV infection or the adverse consequences of infection include the following groups: • Persons who plan to travel repeatedly or reside for long periods in counties with high or intermediate endemicity of HAV infection (see Figure 1 ). • Children in communities with high rates of hepatitis A and periodic hepatitis A outbreaks. • Homosexual men. • Intravenous drug users. • Persons with occupational risk for infection. • Persons with chronic liver disease. • Persons with clotting factor disorders.
Pre-vaccination testing. Prior HAV infection produces lifelong immunity to hepatitis A. Although vaccination of a person immune because of prior infection does not increase the risk for adverse events, pre-vaccination testing may be considered to reduce costs, especially for populations with a high prevalence of immunity to hepatitis A. The cost of a 1 mL dose of Havrix is about $55.00. A test for anti-HAY antibodies in one large clinical laboratory costs about $50.00 (Abramowicz, 1995) . Testing for antibodies could cost less than two HBsAg Prevalence doses of the vaccine. However, the cost of "time away from the workplace" necessary for antibody testing should be factored into the cost/benefit analysis.
Post-vaccination testing. The CDC (1996a) does not recommend post-vaccination serologic testing due to the high rate of vaccine response among both children and adults.
Post-exposure vaccination. Persons recently exposed to HAV who have not previously received the hepatitis A vaccine should be given IG. It is 80% to 90% effective when given post-exposure early in the incubation period and declines thereafter (Alter, 1994) . IG should be administered within 2 weeks of exposure (Perrillo, 1997) .
Occupational and Environmental Health Issues
General infection control measures in the workplace include but are not limited to the following (Gerberding, 1994) rheal illnesses cannot resume their duties until a culture provides evidence that they are cured (Gerberding, 1994) .
Travelers should receive the first dose of hepatitis A vaccine at least 4 weeks before travel. In general, the risk of infection increases with duration of travel, and is highest for those who live in or visit rural areas or frequently eat or drink in settings of poor sanitation. However, many cases of travel related hepatitis A occur in travelers who report that they observe measures to protect themselves against enteric infection or stay only in urban areas or luxury hotels (CDC, 1996a).
HEPATITIS B Background
The hepatitis B virus is a DNA containing virus . The outer surface membrane contains the hepatitis B surface antigen (HBsAg) which also circulates in the blood as circular and tubular particles. The inner core of the virus contains hepatitis B core antigen (HBcAg), hepatitis B e antigen (HBeAg), a single molecule of partially double stranded DNA, and DNA dependent DNA polymerase (CDC, unpublished data). HBeAg, HBV DNA, and DNA polymerase may be detectable in the serum and indicate the presence of replicating virus and increased infectivity (perrillo, 1997).
Epidemiology
Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide. Chronic HBV infection is found in 0.5% of adults in North America and in 0.1 % to 20% of people in other parts of the world (Benenson, 1995) . The ..
Hepatitis B Laboratory Tests
• The hepatitis B surface antigen (HBsAg) can be detected in the serum from several weeks before the onset of symptoms to days, weeks , or months after the onset of symptoms. HBsAg persists in chronic hepatitis B infections. All persons who are HBsAg positive are potentially infectious. • The hepatitis B core antibody (Anti-HBc) appears at the onset of illness and persists indefinitely. Presence of anti-HBc indicates either current or past HBV infection. • The hepatitis B surface antibody (anti-HBs) follows infection or vaccination, indicat ing protective immunity. • The hepatitis Be antigen (HBeAg) and antibody to HBeAg (anti-HBe) reflect infectiousness of the individual. The presence of HBeAg in serum is associated with relatively high infectivity, while those who are positive for anti-HBe may be considered "sparingly infectious" (Benenson, 1995) .
highest prevalence ofHBV infection is found among persons born in areas of high HBV endemicity and their descendants, intravenous drug users , and homosexual men (CDC , 1990) . Highly endemic areas include certain parts of Africa, Asia, South America, etc. (see Figure 2 ).
Transmission
The hepatitis B surface antigen (HBsAg) has been found in nearly all body secretions and excretions. However; only blood (and serum derived fluids), saliva, semen, and vaginal fluids have been shown to be infectious (Benenson, 1995) .
Transmission occurs by permucosal (mucus membrane) or percutaneous (IV, 1M, SC, intradermal) exposure to infectious body fluid s. Examples of permucosal exposure include sexual and perinatal HBV tran smission .' Percutaneous exposures to contaminated fluids may be secondary to transfusion of blood or blood products , sharing needles during drug use, hemodialysis, acupuncture, tattooing, needlesticks, and exposure via other contaminated sharp equipment. HBV is stable on environmental surfaces for 7 days or longer. Therefore, indirect inoculation of HBV can occur via contaminated inanimate objects (e.g., razors and toothbrushes). Fecal-oral or vectorborne transmission has not been demonstrated. In about 35% of cases, no transmission source can be identified (Benenson, 1995) . Perinatal transmission (from mother to newborn) is common, especially when the HBsAg positive mother is also HBeAg positive (Benenson, 1995) .
Diagnosis
Diagnosis is confirmed by identification of specific antigens and/or antibodies. The laboratory tests described in the Sidebar are clinically useful.
Course of InfectIon
The incubation period for hepatitis B infection is usually 45 to 180 days (average, 60 to 90). Many cases of hepatitis B go unrecognized, since only 10% of children and 30% to 50% of adults with acute hepatitis B virus infection will have icteric disease. Among those with clinical illness, the onset is insidious with somewhat vague symptoms, including anorexia, vague abdominal discom-210 fort, nausea and vomiting , possible arthralgias and rash, often progressing to jaundice. Fever may be mild or absent (Benenson, 1995) . Most symptomatic individuals recover within 6 weeks of onset of the illness . However, fatigue can continue for several months (Main, 1997) .
Chronic HBV infection is defined by the presence of the virus (seurm HBsAg positive) for more than 6 months (Main, 1997) . Chronic infection with HBV occurs in 5% to 10% of healthy adults (Alter, 1994) . Immunodeficient adults have a higher risk of chronic infection (Main, 1997) . The risk of developing chronic HBV infection decrease s with age: about 90% of newborns infected develop chronic hepatitis B, representing a significant source of chronic hepatitis B infection (Alter, 1994) . An estimated 15% to 25% of persons with chronic HBV infection die prematurely of either cirrhosis or hepatocellular carcinoma (Alter, 1994) .
Treatment
Alpha interferon is the only drug licensed for treatment of chronic hepatitis B in the United States. Studies have shown that alpha interferon is successful in ceasing viral replication in about 40% of individuals treated. Treatment is most effective in individuals who are HBeAg positive (Benenson, 1995) . Nearly all individuals experience side effects from interferon (e.g., fatigue, myalgias, headaches, fever, and nausea) which usually improve spontaneously over approximately 6 weeks as therapy is continued (Czaja, 1997) . Interferon can enhance the expression of autoimmune manifestations and needs to be used with caution, especially in individuals with concurrent autoimmune diseases (Czaja, 1997) .
EducatlonlPreventlon
General Preventive Practices. Universal precautions must be followed during each instance in which exposure to potentially infectious body fluids is anticipated. Equipment contaminated with blood or infectious body fluids needs to be appropriately decontaminated.
Vaccination. Prophylaxis against infection with the hepatitis B virus can be obtained through either the hepatitis B vaccination or hepatitis B immune globulin (HBIG). The hepatitis B vaccine provides long term protection against HBV infection and is recommended for both pre-exposure and post-exposure prophylaxis. HBIG provides short term protection and is indicated in certain post-exposure situations (CDC, 1991c) .
Two types of hepatitis B vaccines have been licensed in the United States. The initial vaccine was manufactured from the plasma of individuals with chronic HBV infections. Hepatitis B vaccines made from recombinant DNA technology have been available since 1986. Currently, only hepatitis B vaccines produced by recombinant DNA technology are available in the United States. One is manufactured by Merck and Co. (Recombivax HB) and the other by SmithKline Biologicals (Engerix-B). A series of three intramuscular doses of hepatitis B vaccine induces a protective antibody response in more than 90% of healthy adults. The second and third dose should be administered at 1 and 6 months, respectively, after the first. Hepatitis B vaccine should be administered only in the deltoid muscle of adults (CDC, 1991c) .
The immune response demonstrated when one or two doses of a vaccine produced by one manufacturer are followed by subsequent doses from a different manufacturer has been comparable with that resulting from a full course of vaccination with a single vaccine (CDC, 1991c) . Therefore, Recombivax HB and Engerix-B may be used interchangeably in a series for an individual.
The duration of vaccine induced immunity has been evaluated through long term studies which concluded that immunologic memory remains intact for at least 9 years (CDC, 1991c) . In general, neither booster doses of vaccine nor serologic testing to assess antibody levels are recommended for children and adults with a normal immune status (CDC, 1991c) . The possible need for booster doses will be assessed in the future, as additional information becomes available (CDC, 1991c) .
The United States has adopted a comprehensive approach to eliminating HBV transmission. This includes screening all pregnant women and providing immunoprophylaxis to infants born to potentially infectious mothers; integrating hepatitis B vaccine into current childhood immunization schedules to prevent earlychildhood infections; and providing immunity to teenagers and adults prior to their becoming at risk of infection (CDC, 1991c) .
In addition to the above, the CDC (l991c) • Intravenous drug users.
• Sexually active homosexual and bisexual men.
• Selected groups of sexually active heterosexual men and women, e.g., those diagnosed as having recently acquired other sexually transmitted diseases; prostitutes; and those with a history of sexual activity with more than one partner in the previous 6 months. Pre-vaccination testing. Similar to the HAV vaccine, testing individuals for pre-existing antibodies to HBV (anti-HBs or anti-HBc) is not required. However, it may be desirable from a cost saving standpoint, especially where there is a high level of pre-existing infection. The cost effectiveness estimates of testing depend on the cost of vaccination, the cost of testing for susceptibility, and the expected prevalence of immune persons. The cost of "time away from the workplace" also should be considered during the cost/benefit analysis to determine whether to conduct pre-vaccination testing. The cost of each dose of hepatitis B vaccine is approximately $50.00.
Post-vaccination testing. Post-vaccination testing should be considered for persons at occupational risk (e.g., health care workers), as knowledge of their antibody response may assist in determining appropriate post-exposure prophylaxis. Post vaccination testing should be conducted between 1 and 6 months after completion of the vaccine series. Revaccination with one or more additional doses should be considered for persons who do not initially respond to the vaccination. The CDC reports that 15% to 25% produce an adequate antibody response after one additional dose and 30% to 50% after three additional doses of the hepatitis B vaccine (CDC, 1991c) .
Post-exposure vaccination. The CDC outlines specific recommendations for hepatitis B prophylaxis following percutaneous exposure of vaccinated and unvaccinated individuals. For detailed information, the reader is encouraged to refer to Appendix A, CDC (l991c).
Occupational and Environmental Health Issues
All health care workers who may be exposed to blood in an occupational setting should receive the hepatitis B vaccine, preferably before any occupational exposures could occur, such as during professional education and training (CDC, 1991b) .
The CDC (1991b) has provided recommendations for health care workers for preventing transmission of hepatitis B virus to clients during exposure prone invasive procedures. An invasive procedure is defined as "surgical entry into tissues, cavities, or organs or repair of major traumatic injuries" (CDC, 1991b) . According to the CDC (l991b), infected health care workers (HCWs) who do not perform invasiveprocedures and who follow universal precautions do not pose a risk for transmitting HBV to clients. HCWs who perform exposure prone procedures and who do not have serologic evidence of immunity to HBV should know their HBsAg status and, if HBsAg is positive, also should know their HBeAg status. HCWs who are HBeAg positive should not perform exposure prone procedures unless they have sought counsel from an expert review panel and have been advised under what circumstances, if any, they may continue to perform these procedures. The CDC (1991) does not recommend mandatory testing of HCWs. Rather, compliance by HCWs with recommendations should be increased through education, training, and appropriate confidentiality measures.
Vaccination should be considered for international travelers who plan to spend more than 6 months in areas with moderate to high rates of HBV infection (see Figure 2) and who will have close contact with the local population. Short term travelers likely to have contact with blood (e.g., in a medical, dental, or other health care setting) or sexual contact with residents of areas with high or intermediate levels of endemic disease should be vaccinated. Vaccination needs to begin at least 6 months before travel to allow for completion of the full vaccine series, although a partial series offers some protection (CDC, 1991c) .
HEPATITIS C Background
The hepatitis C virus (HCV) is a small, enveloped, cytopathic RNA virus. The HCV is the agent responsible for most cases of post-transfusion nonA-nonB hepatitis (Perrillo, 1997) . Serologic tests detecting antibodies to the hepatitis C virus (anti-HCV) were licensed and became commercially available in the United States in May 1990 (CDC, 1991a) .
Epidemiology
Hepatitis C is widely prevalent throughout the world. It is parenterally transmitted and was the most common cause of post-transfusion hepatitis in the past. Currently, donor screening is conducted for HCV, and <5% of HCV infections are associated with blood transfusion. The prevalence of antibodies to HCV is (Benenson, 1995): • Highest in intravenous drug users and individuals with hemophilia (70% to 90%). • Moderate in persons on hemodialysis (10% to 20%). • Low in heterosexuals with multiple sexual partners, homosexual men, health care workers, and family contacts of HCV infected persons (I % to 5%). • Lowest in volunteer blood donors (0.3% to 0.5%).
Transmission
The incubation period ranges from 2 weeks to 6 months; most commonly 6 to 9 weeks (Benenson, 1995) . The period of communicability for hepatitis C begins from I or more weeks before the onset of the first symptoms and may persist in most persons indefinitely (Benenson, 1995) .
Transmission of the HCV occurs by percutaneous exposure to contaminated blood and plasma derivativesor via contaminated needles and syringes. The risk of HCV transmission by household contact and sexual activity has not been well defined, and transmission in these settings appears to be low. Unlike hepatitis B, transmission from mother to child appears to be uncommon. The risk factors cannot be identified in over 40% of cases of HCV infection (Benenson, 1995) .
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Diagnosis
Hepatitis C infection is currently diagnosed using a recently developed second generation assay (EIA) which has also been established as a screening test for blood donors. Diagnosis depends on demonstration of antibody to the hepatitis C virus (anti-HCV). Anti-HCV is generally not detectable by EIA in individuals with early signs or symptoms of hepatitis C. Some persons may not test positive for 6 to 9 months after the onset of illness. Although some individuals have demonstrated false positives with this screening test, supplemental tests are available to help distinguish true infections. Tests are not yet available to distinguish acute from chronic HCV infection (Benenson, 1995) .
Course of Infection
Although approximately 25% of HCV infections are apparent initially (i.e., 25% of individuals become ill with jaundice and clinical symptoms), chronic infection is common with more than 60% developing chronic liver disease. Of those with chronic disease, 30% to 60% may develop chronic active hepatitis and 5% to 20% may develop cirrhosis (Benenson, 1995) . HCV has also been associated with the development of hepatocellular carcinoma. However, a direct link has not yet been established (CDC, 1991a) .
Treatment
Although chronic liver disease is a frequent outcome of hepatitis C, chronic liver disease may take years to develop and the majority of infected individuals may be asymptomatic. However, some individuals do suffer from severe disease and recent studies have reported that alpha interferon therapy may have a beneficial effect among some persons (CDC, 1991a) .
EducationlPrevention
General Preventive Practices. General infection control measures identified for HBV apply for HCV. Use of IG for HCV prophylaxis is not clear. Blood banks discard donor units positive for anti-HBc and/or units with elevated liver enzymes, regardless of whether or not the test for anti-HCV is positive (CDC, 1991a) .
Vaccination. No vaccine is currently available.
Occupational and Environmental Health Issues
Individuals with HCV infection are at risk for developing chronic liver disease. The nurse should be supportive and provide counseling as needed.
All individuals found to be anti-HCV positive need to be considered potentially infectious and should be counseled concerning infectivity. The CDC (1991a) has developed recommendations for counseling which include the following: • Individuals should not donate blood, body organs, other tissue, or semen. • Household articles such as toothbrushes and razors that could be contaminated with blood should not be shared, and cuts or skin lesions should be covered to prevent the spread of infectious secretions or blood.
• The magnitude of the risk of infecting others by sexual intercourse in unknown, but appears to be much less than that for other bloodborne sexually transmitted diseases (HBV and HIV). Although transmission of HCV rarely has been documented from persons with chronic disease to their steady sexual partners, having multiple sexual partners has been associated with an increased risk of acquiring hepatitis C. The CDC (1996b) currently has no recommendations related to work restrictions for health care workers with hepatitis C. However, as recommended for all health care workers, individuals positive for anti-HCV must follow strict aseptic technique and standard universal precautions.
HEPATITIS D Background
The hepatitis delta virus (HDV) is a defective virus that causes infection only in the presence of active HBV infection. HDV infection occurs as either co-infection with HBV or superinfection in persons who are HBV carriers.
Epidemiology
HDV infection has a worldwide distribution. The areas of highest endernnicity are in Russia, Romania, Southern Italy, Africa, and South America (Benenson, 1995) . In areas of Southeast Asia and China, where the prevalence of chronic HBV is very high, HDV is uncommon. Periodic epidemics of HDV infection among chronic HBV carriers in relatively isolated regions of the South American countries in the Amazon River Basin have resulted in very severe disease with rapid progression to fulminant hepatitis and high case fatality rates of 10% to 20% (CDC, unpublished data).
Transmission
The modes of transmission of HDV are similar to those for HBV, with percutaneous exposures the most efficient (Alter, 1994) . Sexual transmission of HDV is less efficient than for HBY. Perinatal HDV transmission is rare and has not been documented to occur in the United States (Alter, 1994) .
The incubation period is approximately 2 to 8 weeks. Blood is potentially infectious during all phases of active delta hepatitis infection, with peak infectivity probably just prior to onset of acute illness (Benenson, 1995) .
Diagnosis
Diagnosis is made by detection of total antibody to HDV (anti-HDV) (Benenson, 1995) .
Course of Infection
The onset of illness is usually abrupt, with signs and symptoms resembling those of hepatitis B. Delta hepatitis may be self limiting or it may progress to chronic hepatitis. HDV and HBV may co-infect an individual, or the HDV may superinfect a person with chronic HBV infection (Benenson, 1995) . Whereas coinfection usually resolves, superinfection frequently causes chronic HDV infection and chronic active hepatitis (CDC, 1991c) . APRIL 1998, VOL. 46, NO.4 Treatment Treatment of hepatitis D is supportive. Interferon may be beneficial (Main, 1997) .
Education/Prevention
General Preventive Measures. HBV-HDV co-infection can be prevented with either pre-exposure or postexposure prophylaxis for HBY. However, no existing products prevent HDV superinfections of HBsAg carriers. Therefore, prevention of HDV superinfection among HBsAg carriers relies on education to reduce high risk behaviors (Alter, 1994) .
Vaccination. No vaccination for HDV exists. However, HBV-HDV co-infection can be prevented with either pre-exposure or post exposure prophylaxis for HBY.
Occupational and Environmental Health Issues
Methods of control for HDV are similar to those for the HBV (Benenson, 1995) .
HEPATITIS E
Background Hepatitis E is sometimes referred to as "enterically transmitted non-A non-B hepatitis." Outbreaks of hepatitis E occur primarily in countries with inadequate sanitation, often as (fecally contaminated) waterborne epidemics (Benenson, 1995) .
Epidemiology
Hepatitis E cases have been documented in travelers returning home from HEV-endemic areas. Outbreaks have been reported in India, Myanmar (Burma), Iran, Bangladesh, Ethiopia, Nepal, Pakistan, Central Asian Republics of the former Soviet Union, Algeria, Libya, Somalia, Mexico, Indonesia, and China (Benenson, 1995) .
Transmission
HEV is transmitted by the fecal-oral route. Fecally contaminated drinking water has been the most commonly documented vehicle of transmission (Alter, 1994) . The role of person to person contact in HEV transmission is unclear (Alter, 1994) . Bloodborne transmission has not been demonstrated (Perrillo, 1997) .
The incubation period for HEV ranges from 15 to 64 days, with a mean incubation period ranging from 26 to 42 days in different epidemics. The period of communicability is not known. However, HEV has been detected in stools 14 days after the onset of jaundice (Benenson, 1995) .
Diagnosis
Although serologic tests for antibody to HEV have been developed, they are available only on a limited basis from research laboratories (Alter, 1994) . Diagnosis usually depends on clinical and epidemiologic features and the exclusion of other etiologies of hepatitis, especially hepatitis A (Benenson, 1995) .
Course of Infection
The clinical course of hepatitis E infection is similar to hepatitis A, with no evidence of chronic infection. In addition, the case fatality rate is similar to that of hepatitis A, except for pregnant women, in which the rate may reach 20% among those infected during the third trimester of pregnancy (Benenson, 1995) .
Treatment
Treatment of hepatitis E is supportive.
EducationlPrevention
General Preventive Practices. It is important to provide educational programs stressing sanitary disposal of feces and careful handwashing after defecation and before handling food (Benenson, 1995) .
Vaccination. No vaccine for the prevention of hepatitis E is available. The efficacy of immune globulin prophylaxis has not been established.
Occupational and Environmental Health Issues
Educational programs need to be provided that stress the importance of good hygiene, careful handwashing, and basic measures to prevent fecal-oral transmission of disease (Benenson, 1995) .
NON-ABCDE VIRAL HEPATITIS
Prior to the identification of the hepatitis C virus, several studies suggested the existence of more than one viral agent associated with parenterally transmitted nonA-nonB hepatitis. Identification of the previously discussed hepatitis entities had not been found in some persons demonstrating post-transfusion and community acquired nonA-nonB viral hepatitis infection. This suggested that these individuals may be infected with an unidentified viral agent or agents referred to as non-ABCDE hepatitis (Alter, 1994) .
Current resources reveal new findings in this area. Main (1997) referred to a virus which, although not yet well understood, was isolated in stools of clients and, like HAV and HEV, is enterically transmitted. This virus is referred to as the "hepatitis F virus". Additional new viruses related to, but distinct from, the hepatitis C virus are being referred to as the "hepatitis G viruses" (Main, 1997) . More information related to these non-ABCDE viruses should be forthcoming.
CHEMICALLY INDUCED HEPATITIS
Background
Chemicals associated with the development of acute liver inflammation may be found in the workplace. These include (Pransky, 1988) : • Chlorinated hydrocarbons: e.g., carbon tetrachloride and chloroform (solvent workers, degreasers, refrigeration workers). • Nitroaromatics: e.g., dinitrophenol (DNP) (chemical indicator workers) and dinitrobenzene (dye workers, explosive workers).
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• Ether: e.g.,Dioxin(herbicide workers, insecticide workers). • Halogenated aromatics: e.g., polychlorinated biphenyls (electrical component assemblies); DDT and chlordecone (insecticide workers, fumigators, disinfectant workers); chlorobenzenes (solvent workers, dye workers); and halothane (anesthesiologists). In many cases, chemical exposures may not result in a full blown picture of hepatitis, but rather a milder form of liver inflammation. This may be characterized by an elevation in liver function tests and a fatty liver.
Epidemiology
In general, the incidence of acute toxic hepatitis in the workplace has decreased due to substitution of certain compounds with less hepatotoxic ones. Nevertheless, cases of acute toxic hepatitis are still reported as a result of accidental inhalation of chemical fumes known to be hepatotoxic (Pransky, 1988) .
Transmission
Acute hepatitis due to chemical exposures usually occurs through inhalation (Pransky, 1988) .
Diagnosis
A history of exposure and elevated liver function tests may point to a diagnosis of acute toxic hepatitis. The health assessment often reveals jaundice and hepatomegaly (Pransky, 1988) . It is important that the assessment not be limited to the abdomen. In addition, evidence of toxicity to other organ systems should be assessed (Redlich, 1994) .
The key to identifying work related acute toxic hepatitis lies in taking a careful occupational and environmental exposure history. The temporal relationship between the onset of exposure and symptoms is essential to identifying acute toxic hepatitis (Redlich, 1994) .
Course of Infection
The symptoms of acute toxic hepatitis are similar to those of acute viral hepatitis and include headache, dizziness, drowsiness, nausea, and vomiting. However, unlike acute viral hepatitis, the symptoms usually begin 12 to 48 hours after exposure and clients do not develop a fever. Individuals with acute toxic hepatitis usually recover within 4 to 6 weeks. Complications and death are infrequent. However, when they do occur, they usually are associated with other conditions such as renal failure (Pransky, 1988) .
Fulminant occupational hepatitis may follow a massive accidental exposure to a hepatotoxin. This condition is potentially fatal, and occurs 1 to 3 days after the exposure. Other organs are also affected, and renal failure and central system depression usually are found (Redlich, 1994) .
Treatment
Treatment for chemically induced occupational hepatitis consists of appropriate supportive measures . The prognosis is favorable for individuals who recover from the acute episode (Redlich, 1994) .
Viral Illnesses That May Result in Hepatitis
• Cytomegalovirus infectioncan be transmitted from close contact such as kissing and sexual intercourse as well as through transfusion. Most adult acquired infectionsare asymptomatic. Although jaundice is rare, viral hepatitis may be simulated and severe cholestaticjaundice and fulminant hepatic failure have been reported. • Epstein-Barrvirus is transmitted by close contact such as kissing. Fulminant hepatitis is very rare and in males, suggests a rare sex linked condition called Duncan's syndrome where the immune system fails to deal with the Epstein-Barr virus. • Herpes simplex virus can cause hepatitis in adults during the primary infection. This is rare but can be life threatening. • Varicellazoster virus (chickenpox) can cause multisystem diseases including liver involvement in immunocompromised adults. • Rubella virus can cause extensive fetal damage which includes hepatomegaly and liver damage at birth. • Measles: Hepatitis is common with measles but is usually asymptomatic and free of chronic complications.
• The yellow fever virus may be transmitted between persons by the mosquito. Lesions in yellow fever are widespread and affect the liver. However, recovery is usually complete. • The Marburg and Ebola viruses both cause hepatitis in illnesses that are clinically indistinguishable. The illness is severe with more than one fourth of victims dying. The liver returns to normal in survivors.
EducationlPrevention
General Preventive Measures. Acute toxic hepatitis can be prevented through identification and evaluation of hazards in the workplace, and use of appropriate controls. Exposure to hepatotoxins must be minimized.
Vaccination. Clearly, no vaccinations exist to prevent chemically induced acute toxic hepatitis.
Occupational and Environmental Health Issues
Preplacement evaluations should include identification of factors that could make the individual especially susceptible to the effects of hepatoxins , such as alcohol or barbiturate abuse. Individuals working with hepatotoxic substances should have periodic liver function tests. When abnormalities are noted with liver function test results, the employee should be removed from the exposure until the cause is identified and controlled (Pransky, 1988) .
When employees present to the nurse with signs and symptoms of acute hepatitis, a careful exposure history and review of alcohol intake need to be conducted. The employee should be referred as appropriate for further testing and evaluation.
HEPATITIS SECONDARY TO OTHER DISEASES
Viral hepatitis due to the hepatitis A through G viruses has been discussed above. Many other viral illnesses can cause hepatitis, which may result in abnormal liver function tests that rapidly return to normal to those that can lead to fatal disease. The viral illnesses described in the Sidebar may result in hepatitis (Main 1997) .
In addition, hepatitis may result as a complication of other infections such as leptospirosis, syphilis, tuberculosis, toxoplasmosis, and amebiasis. Noninfectious causes of hepatitis include: biliary obstruction, primary biliary cirrhosis, Wilson's disease, drug toxicity, and drug hypersensitivity (Melnick, 1995) . APRIL 1998, VOL. 46, NO.4 
CONCLUSION
Although hepatitis may be due to a variety of etiologies, individuals often present with similar signs and symptoms. The nurse should be familiar with the potential etiologies, modes of transmission, and clinical course associated with the various types of hepatitis . A thorough occupational and environmental exposure history is an essential tool when assessing employees with signs and symptoms of hepatitis.
Hepatitis is often preventable. The nurse should be aware of control measures for viral hepatitis . Pre-exposure and immediate post-exposure vaccinations can serve as primary and secondary preventive measures for hepatitis A and B, and co-infection with the hepatitis D virus. Proper hygiene, and cautious eating and drinking can prevent the fecal-oral transmission of hepatitis A and E. Universal precautions can prevent transmission of hepatitis B, C, and D (see the Table for specific comparisons). Control of chemical exposures in the workplace reduces the risk of developing acute toxic hepatitis.
The nurse may need to address return to work issues for individuals with a diagnosis of hepatitis. Knowledge and understanding of the course of infection as well as infectivity and modes of transmission is essential. Several resources for hepatitis information are available. These are described in the Sidebar on page 217. r---------------------I 
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Hepatitis may be caused by a variety of agents, including viruses (e.g., hepatitis A-E viruses) and certain chemicals (e.g., acute toxic hepatitis from exposure to hepatotoxins). Hepatitis also may occur secondary to other illnesses (e.g., tuberculosis, bilary obstruction, etc.).
The nurse needs to be aware of potential etiologies, modes of transmission, and the clinical course associated with the various types of hepatitis.
Hepatitis is often preventable. The nurse should be aware of control measures for viral hepatitis which include pre-exposure and post-exposure vaccinations, the use of universal precautions, proper hygiene practices, and cautious eating and drinking. Control of chemical exposures in the workplace reduces the risk of developing acute toxic hepatitis.
